Short-Term Effect of Prostaglandin Group Antiglaucomatous Drugs on Choroid Thickness

Yıl 2024, Cilt: 14 Sayı: 1, 1 - 7, 30.04.2024

Müslüm Toptan , Ali Şimşek

Öz

Aim: To evaluate the effects of patients with whom we started prostaglandin analogues for primary open-angle glaucoma (POAG) by measuring the choroidal thickness with Enhanced-Depth Imaging - Optical Coherence Tomography (EDI-OCT).
Material and Method: Thirty-two eyes of 32 patients (Group 1) in whom prostaglandin analogues antiglaucomatous drops were initiated, 32 eyes of 32 patients (Group 2) who were initiated with different groups of antiglaucomatous drugs, and 32 eyes of 32 healthy individuals (control group) were included in the study. Before the drug, these groups’ submacular choroidal thickness (CT) and intraocular pressure (IOP) were measured with EDI-OCT. Submacular CT of the same groups was measured in the 1st week, the 1st month, and the 3rd month after starting the drug..
Results: A significant increase was detected in mean submacular CT thickness measurements with drug use in both Group 1 and Group 2 (p<0.001). Although the choroidal thickness was thinner in pre-treatment glaucoma groups, there was no significant difference in CT (p=0.072). There was no statistically significant difference between the mean Submacular CT groups of all groups at three months (p=0.198). The decrease in IOP in the glaucoma groups was statistically significant (p<0.001, p<0.001, respectively).
Conclusion: A significant increase in submacular CT values was detected in patients who started prostaglandin or non-prostaglandin antiglaucomatous due to POAG. In addition, no statistically significant difference was found between the glaucoma groups regarding choroidal change.

Anahtar Kelimeler

choroidal thickness, optical coherence tomography, prostaglandin analogues, intraocular pressure

Kaynakça

• 1. Ho H, Daas A, Ho J, Alaghband P, Galvis EA, de Antonio Ramirez A, et al. Intraocular pressure changes following topical ocular hypotensive medications washout. Br J Ophthalmol. 2021;105:205–9.
• 2. Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96(3):e277–e284.
• 3. Yildirim N, Sahin A, Gultekin S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma. 2008;17:36–9.
• 4. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53:107–20.
• 5. Stjernschantz J, Selén G, Astin M, Resul B. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Prog Retin Eye Res. 2000;19:459–96.
• 6. Harris A, Garzozi HJ, McCranor L, Rechtman E, Yung CW, Siesky B. The effect of latanoprost on ocular blood flow. Int Ophthalmol. 2009;29:19–26.
• 7. Polska E, Simader C, Weigert G, Doelemeyer A, Kolodjaschna J, Scharmann O, et al. Regulation of choroidal blood flow during combined changes in intraocular pressure and arterial blood pressure. Invest Ophthalmol Vis Sci. 2007;48:3768–74.
• 8. Lee D, Mantravadi AV, Myers JS. Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution. Clin Ophthalmol. 2017;11:1273–80.
• 9. Cheggour M, Gambrelle J. [Massive choroidal detachment secondary to topical use of bimatoprost: Report of two cases]. J Fr Ophtalmol. 2012;35:176–80.
• 10. Park Y, Kim HK, Cho KJ. Comparison of peripapillary and macular choroidal thickness and ganglion cell complex thickness in glaucomatous and healthy eyes. Int J Ophthalmol. 2019;12:603–6.
• 11. Zhang Z, Yu M, Wang F, Dai Y, Wu Z. Choroidal Thickness and Open-Angle Glaucoma: A Meta-Analysis and Systematic Review. J Glaucoma. 2016;25:e446–54.
• 12. Mwanza JC, Hochberg JT, Banitt MR, Feuer WJ, Budenz DL. Lack of association between glaucoma and macular choroidal thickness measured with enhanced depth-imaging optical coherence tomography. Invest Ophthalmol Vis Sci. 2011;52:3430–5.
• 13. Maul EA, Friedman DS, Chang DS, Boland MV, Ramulu PY, Jampel HD, et al. Choroidal thickness measured by spectral domain optical coherence tomography: factors affecting thickness in glaucoma patients. Ophthalmology. 2011;118:1571–9.
• 14. Song YJ, Kim YK, Jeoung JW, Park KH. Assessment of Open-Angle Glaucoma Peripapillary and Macular Choroidal T hickness Using Swept-Source Optical Coherence Tomography (SS-OCT). PLoS One. 2016;11(6):e0157333.
• 15. Vetrugno M, Cardascia N, Cantatore F, Sborgia C. Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary openangle glaucoma: A prospective, open-label, randomized, two-arm, parallel-group study. Curr Ther Res Clin Exp. 2004;65:444–54.
• 16. Reitsamer HA, Kiel JW. A rabbit model to study orbital venous pressure, intraocular pressure, and ocular hemodynamics simultaneously. Invest Ophthalmol Vis Sci. 2002;43:3728–34.
• 17. Fuchsjager-Mayrl G, Georgopoulos M, Hommer A. Effect of dorzolamide and timolol on ocular pressure: blood flow relationship in patients with primary open-angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci. 2010;51:1289–96.
• 18. Martinez A, Sanchez-Salorio M. Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0. 5% in primary open-angle glaucoma. Acta Ophthalmol. 2010;88:541–52.
• 19. Çalişkan S, Uğurbaş SC, Alpay A, Uğurbaş SH. Changes in the Choroidal Thickness and Axial Length Upon Mannitol Infusion in Patients With Asymmetric Intraocular Pressure. J Glaucoma. 2016;25:891–5.
• 20. Akahori T, Iwase T, Yamamoto K, Ra E, Terasaki H. Changes in Choroidal Blood Flow and Morphology in Response to Increase in Intraocular Pressure. Invest Ophthalmol Vis Sci. 2017;58:5076–85.
• 21. Caprioli J, Coleman AL. Blood Flow in Glaucoma Discussion. Blood pressure, perfusion pressure, and glaucoma. Am J Ophthalmol. 2010;149:704–12.
• 22. Kola M, Kalkisim A, Karkucak M, Turk A, Capkin E, Can I, et al. Evaluation of choroidal thickness in ankylosing spondylitis using optical coherence tomography. Ocul Immunol Inflamm. 2014;22:434–8.
• 23. Boyraz S, Aritürk N. The Effect on Macular Thickness of Prostaglandin Group Eye Drops for Glaucoma. Glo-Kat. 2010;5:75–8.
• 24. Nakakura S, Yamamoto M, Terao E, et al. The whole macular choroidal thickness in subjects with primary open angle glaucoma. PLoS One 2014;9(10):e110265. Nakakura S, Yamamoto M, Terao E, Nagasawa T, Tabuchi H, Kiuchi Y. The whole macular choroidal thickness in subjects with primary open angle glaucoma. PLoS One. 2014;9:e110265.
• 25. Hirata M, Tsujikawa A, Matsumoto A, Hangai M, Ooto S, Yamashiro K, et al. Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci. 2011;52:4971–8.
• 26. Akyol N, Kalkisim A, Turk A, Kola M, Imamoglu HI. Evaluation of the effects on choroidal thickness of bimatoprost 0. 03% versus a brinzolamide 1. 0%/timolol maleate 0. 5% fixed combination. Cutan Ocul Toxicol. 2017;36:397–403.
• 27. Aksoy Y, Çolakoglu K, Kar T, Sevinc MK, Eyi YE. Choroidal thickness is affected by more factors than estimated. Invest Ophthalmol Vis Sci. 2014;55:1311.
• 28. Usui S, Ikuno Y, Akiba M, Maruko I, Sekiryu T, Nishida K, et al. Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects. Invest Ophthalmol Vis Sci. 2012;53:2300–7.